1-(4-Ethylpiperazin-1-yl)-2,2-dimethylpropan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-Ethylpiperazin-1-yl)-2,2-dimethylpropan-1-one
• 化学式: C₁₁H₂₂N₂O
• mdl: MFCD03392140
• 分子量: 198.308
• InChiKey: KPMXKTVNRGEGNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-乙基哌嗪 、 三甲基乙酸 在 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 1-(4-Ethylpiperazin-1-yl)-2,2-dimethylpropan-1-one
  参考文献：
  名称：

  Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors

  摘要：

  A series of adamantyl amide 11 beta-HSD1 inhibitors has been discovered and chemically modified. Selected compounds are selective for 11 beta-HSD1 over 11 beta-HSD2 and possess excellent cellular potency in human and murine 11 beta-HSD1 assays. Good pharmacodynamic characteristics are observed in ex vivo assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.057

文献信息

• NOVEL AZABICYCLOHEXANES
  申请人：Jain Rajseh

  公开号：US20120165320A1

  公开（公告）日：2012-06-28

  The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

  本发明涉及公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体包括R和S异构体，多晶型，前药，代谢物，盐或溶剂的形式。该发明还涉及用于合成公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，多晶型，前药，代谢物，盐或溶剂的过程。
• AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY
  申请人：Shenzhen TargetRx, Inc.

  公开号：US20190152954A1

  公开（公告）日：2019-05-23

  An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.

  一种用于抑制蛋白酪氨酸激酶活性的氨基嘧啶化合物，其制药组合物、制备方法及应用。具体来说，一种由式（I）表示的氨基嘧啶化合物，其中规范中定义了R1、R2、L、Y、R6、W、A、m和n，以及其药用可接受的盐、立体异构体、溶剂化合物、水合物、多形性、前药或同位素变体。该化合物可用于治疗和/或预防蛋白酪氨酸激酶相关疾病，如细胞增殖性疾病、癌症和免疫性疾病。
• Heterobicyclic thiophene compounds and methods of use
  申请人：Blake F. James

  公开号：US20070197537A1

  公开（公告）日：2007-08-23

  Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物及其药用盐可用于抑制受体酪氨酸激酶，并用于治疗由此介导的疾病。公开了使用公式I的化合物及其药用盐的方法，用于体外、原位和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理情况。
• QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150148344A1

  公开（公告）日：2015-05-28

  This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 7 , W, X, and Z are as described herein.

  本申请涉及可能作为溴结构域含蛋白质的抑制剂或以其他方式调节其活性的化合物，包括溴结构域含蛋白质4（BRD4），以及含有这些化合物的组合物和配方，以及使用和制备这些化合物的方法。化合物包括式I的化合物，其中R1、R2、R3、R4、R7、W、X和Z如本文所述。
• Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20140378429A1

  公开（公告）日：2014-12-25

  The disclosure relates particularly to certain carboxamide, sulfonamide and amine compounds and pharmaceutical compositions thereof, and to methods of treating and ameliorating disorders and conditions related to the adiponectin pathway, sphingolipid metabolism, oxidative stress, mitochondrial dysfunction, free radical damage and metabolic inefficiency, among others. In certain embodiments, the compounds have the structures (I-1), (2-I) and (3-I) (The chemical formulas should be inserted here) in which the variables are as described herein.

  本公开涉及特定的羧酰胺、磺酰胺和胺化合物及其制药组合物，以及治疗和改善与脂联素途径、鞘脂代谢、氧化应激、线粒体功能障碍、自由基损伤和代谢效率等相关的疾病和病症的方法。在某些实施例中，化合物具有结构（I-1）、（2-I）和（3-I）（化学式应在此处插入），其中变量如本文所述。